Blasts 20-30 Percent of Bone Marrow Nucleated Cells
2 clinical trials · Condition
◉ Watch Blasts 20-30 Percent of Bone Marrow Nucleated Cells
| Record | Firm | Date |
|---|---|---|
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (NCT03383575) | M.D. Anderson Cancer Center | 2018-01-17 |
| Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome (NCT03047993) | M.D. Anderson Cancer Center | 2017-11-15 |
Track Blasts 20-30 Percent of Bone Marrow Nucleated Cells automatically
Every clearance here is in the API, with alerts when new ones post.